GeneOne Life Science, Inc. (KRX:011000)

GeneOne Life Science Balance Sheet

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	749.78	1,180	9,111	13,261	22,310	62,432
Short-Term Investments	1,900	566.19	406.6	32,342	85,094	28,086
Trading Asset Securities	73.97	-	470.79	-	-	-
Cash & Short-Term Investments	2,723	1,746	9,988	45,603	107,404	90,518
Cash Growth	-39.49%	-82.52%	-78.10%	-57.54%	18.65%	417.94%
Accounts Receivable	5,100	7,182	6,624	8,980	7,438	7,408
Other Receivables	135.21	1,050	948.44	1,598	1,975	374.05
Receivables	5,310	8,310	7,652	10,659	10,091	8,401
Inventory	15,441	16,511	14,897	14,864	10,688	8,299
Prepaid Expenses	1,029	1,542	1,225	1,145	706.46	1,226
Other Current Assets	403.16	525.52	811	793.08	5,744	315.08
Total Current Assets	24,907	28,635	34,573	73,063	134,633	108,760
Property, Plant & Equipment	97,868	117,730	111,399	144,369	110,382	22,427
Long-Term Investments	18.93	18.5	50.39	147.49	437.33	710.58
Other Intangible Assets	184.75	189.96	385.99	563.91	643.1	683.11
Long-Term Deferred Tax Assets	20.03	21.71	13.28	36.42	14.24	154.29
Other Long-Term Assets	3,674	4,739	4,586	4,687	4,735	3,750
Total Assets	126,672	151,334	151,008	222,867	250,857	136,571
Accounts Payable	20,468	20,176	10,066	7,493	17,531	6,881
Accrued Expenses	4,051	4,910	1,971	2,327	1,173	931.56
Short-Term Debt	4,462	3,377	2,405	12,246	9,754	15,634
Current Portion of Leases	2,691	2,895	2,396	1,911	1,543	1,337
Other Current Liabilities	11,714	11,147	6,029	9,858	4,758	11,920
Total Current Liabilities	43,386	42,506	22,867	33,836	34,759	36,705
Long-Term Debt	15,640	16,373	6,273	-	-	-
Long-Term Leases	3,094	4,480	6,085	5,509	7,103	794.09
Long-Term Deferred Tax Liabilities	142.87	154.83	323.98	457.33	144.32	-
Other Long-Term Liabilities	1,863	2,192	1,872	1,594	1,524	473.64
Total Liabilities	64,179	65,729	39,518	41,395	44,350	38,062
Common Stock	84,917	80,039	78,474	77,752	77,479	44,771
Additional Paid-In Capital	222,672	217,579	215,555	214,299	209,871	117,319
Retained Earnings	-289,095	-264,848	-216,231	-137,155	-98,241	-81,567
Treasury Stock	-2,955	-2,955	-2,955	-2,955	-2,955	-2,371
Comprehensive Income & Other	46,954	55,791	36,647	29,531	20,353	20,357
Shareholders' Equity	62,493	85,605	111,489	181,471	206,507	98,509
Total Liabilities & Equity	126,672	151,334	151,008	222,867	250,857	136,571
Total Debt	25,887	27,126	17,160	19,666	18,400	17,766
Net Cash (Debt)	-23,164	-25,379	-7,171	25,937	89,004	72,752
Net Cash Growth	-	-	-	-70.86%	22.34%	2333.27%
Net Cash Per Share	-458.72	-319.41	-92.24	334.73	1198.84	1205.09
Filing Date Shares Outstanding	84.71	79.83	78.26	77.54	77.27	66.9
Total Common Shares Outstanding	84.71	79.83	78.26	77.54	77.27	66.9
Working Capital	-18,480	-13,870	11,705	39,227	99,875	72,055
Book Value Per Share	737.75	1072.35	1424.52	2340.29	2672.55	1472.58
Tangible Book Value	62,308	85,415	111,103	180,907	205,864	97,826
Tangible Book Value Per Share	735.57	1069.97	1419.59	2333.02	2664.23	1462.37
Land	3,354	3,720	3,139	4,081	3,817	3,503
Buildings	69,707	76,192	63,374	1,403	1,331	1,328
Machinery	55,495	55,318	48,599	15,199	11,775	9,776
Construction In Progress	-	-	-	104,661	78,283	11,489
Leasehold Improvements	16,783	16,414	14,867	13,139	12,124	6,739

Source: S&P Global Market Intelligence. Standard template. Financial Sources.